The granted claims of the patents from China, Israel, Mexico, Singapore, Sri Lanka include the class of selective 5-HT compounds discovered by Suven
Suven Life Sciences has received one product patent each from China (CN 102869647), Israel (220709), Mexico (329382), Singapore (181992) and from Sri Lanka (15412) corresponding to their new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents, which are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, parkinson and schizophrenia.
“We are pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, Chief Executive Officer, Suven.